RT Journal Article
SR Electronic
A1 Misra-Press, Anita
T1 Novel Compound Beneficial as Adjunct to Antibody-Based Therapy for Stage IV NSCLC Patients
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 8
SP 14
OP 15
DO 10.1177/1559897715588496
UL http://mdc.sagepub.com/content/15/8/14.2.abstract
AB This randomized, phase 2 trial evaluated PGG beta-glucan, a novel immune modulator, in combination with bevacizumab and carboplatin/paclitaxel as first-line treatment for patients with stage IV non–small cell lung cancer. Though not statistically significant, the results for the primary and secondary end points favor the PGG beta-glucan–treated group and warrant further study of PGG beta-glucan as an adjunct to bevacizumab-containing chemotherapy regimens.